دورية أكاديمية
أعرض في EDS

The Translocator Protein ( TSPO ) Genetic Polymorphism A147T Is Associated with Worse Survival in Male Glioblastoma Patients.

التفاصيل البيبلوغرافية
العنوان: The Translocator Protein ( TSPO ) Genetic Polymorphism A147T Is Associated with Worse Survival in Male Glioblastoma Patients.
المؤلفون: Troike KM; Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA., Acanda de la Rocha AM; Department of Environmental Health Sciences, Robert Stempel College of Public Health & Social Work, Florida International University, Miami, FL 33199, USA., Alban TJ; Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA., Grabowski MM; Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.; Department of Neurosurgery, Cleveland Clinic, Cleveland, OH 44195, USA., Otvos B; Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.; Department of Neurosurgery, Cleveland Clinic, Cleveland, OH 44195, USA., Cioffi G; National Cancer Institute, Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, Bethesda, MD 20892, USA., Waite KA; National Cancer Institute, Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, Bethesda, MD 20892, USA., Barnholtz Sloan JS; National Cancer Institute, Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, Bethesda, MD 20892, USA.; National Cancer Institute, Center for Biomedical Informatics and Information Technology, Bethesda, MD 20892, USA., Lathia JD; Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA.; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA.; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH 44195, USA., Guilarte TR; Department of Environmental Health Sciences, Robert Stempel College of Public Health & Social Work, Florida International University, Miami, FL 33199, USA.; Brain, Behavior & the Environment Program, Robert Stempel College of Public Health & Social Work, Florida International University, Miami, FL 33199, USA., Azzam DJ; Department of Environmental Health Sciences, Robert Stempel College of Public Health & Social Work, Florida International University, Miami, FL 33199, USA.
المصدر: Cancers [Cancers (Basel)] 2021 Sep 08; Vol. 13 (18). Date of Electronic Publication: 2021 Sep 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Glioblastoma (GBM) is the most common primary brain tumor in adults, with few available therapies and a five-year survival rate of 7.2%. Hence, strategies for improving GBM prognosis are urgently needed. The translocator protein 18kDa ( TSPO ) plays crucial roles in essential mitochondria-based physiological processes and is a validated biomarker of neuroinflammation, which is implicated in GBM progression. The TSPO gene has a germline single nucleotide polymorphism, rs6971, which is the most common SNP in the Caucasian population. High TSPO gene expression is associated with reduced survival in GBM patients; however, the relation between the most frequent TSPO genetic variant and GBM pathogenesis is not known. The present study retrospectively analyzed the correlation of the TSPO polymorphic variant rs6971 with overall and progression-free survival in GBM patients using three independent cohorts. TSPO rs6971 polymorphism was significantly associated with shorter overall survival and progression-free survival in male GBM patients but not in females in one large cohort of 441 patients. We observed similar trends in two other independent cohorts. These observations suggest that the TSPO rs6971 polymorphism could be a significant predictor of poor prognosis in GBM, with a potential for use as a prognosis biomarker in GBM patients. These results reveal for the first time a biological sex-specific relation between rs6971 TSPO polymorphism and GBM.
References: Brain. 2000 Nov;123 ( Pt 11):2321-37. (PMID: 11050032)
Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1406-19. (PMID: 23715902)
Adv Pharmacol. 2018;82:103-136. (PMID: 29413517)
J Nucl Med. 2015 Apr;56(4):512-7. (PMID: 25722450)
Oncotarget. 2018 Apr 13;9(28):19980-19993. (PMID: 29731997)
Neuro Oncol. 2018 Mar 27;20(4):576-577. (PMID: 29474647)
FEBS J. 2016 Mar;283(5):803-14. (PMID: 26607558)
Curr Pharm Des. 2007;13(23):2385-405. (PMID: 17692008)
Psychoneuroendocrinology. 2013 Nov;38(11):2826-9. (PMID: 23942012)
Biochim Biophys Acta. 2008 Feb;1782(2):118-25. (PMID: 18190798)
Int J Mol Sci. 2020 Jan 17;21(2):. (PMID: 31963507)
Nat Rev Drug Discov. 2010 Dec;9(12):971-88. (PMID: 21119734)
Pharmacol Ther. 2008 Apr;118(1):1-17. (PMID: 18374421)
Biochem J. 2017 Nov 21;474(23):3985-3999. (PMID: 29074640)
Psychoneuroendocrinology. 2018 Mar;89:194-202. (PMID: 29414032)
Cancer Cell. 2010 Jan 19;17(1):98-110. (PMID: 20129251)
Cancer Cell. 2010 May 18;17(5):510-22. (PMID: 20399149)
Neurobiol Dis. 2004 Apr;15(3):601-9. (PMID: 15056468)
Exp Cell Res. 1998 Jun 15;241(2):426-34. (PMID: 9637784)
Nat Cancer. 2021 Feb;2(2):141-156. (PMID: 33681822)
Trends Pharmacol Sci. 2006 Aug;27(8):402-9. (PMID: 16822554)
Oncotarget. 2017 Apr 4;8(14):23142-23154. (PMID: 28423563)
Endocrinology. 1998 Dec;139(12):4991-7. (PMID: 9832438)
Eur J Biochem. 1991 Jan 30;195(2):305-11. (PMID: 1847678)
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. (PMID: 33123732)
DNA Cell Biol. 1992 Jul-Aug;11(6):471-80. (PMID: 1326278)
J Pak Med Assoc. 2020 Dec;70(12(A)):2291-2293. (PMID: 33475617)
Curr Mol Med. 2012 May;12(4):426-42. (PMID: 22348611)
Neurobiol Dis. 2015 Oct;82:526-539. (PMID: 26388398)
Immunobiology. 2020 Jan;225(1):151853. (PMID: 31703822)
Neuro Oncol. 2017 Jul 1;19(7):887-896. (PMID: 28339582)
PLoS One. 2018 Apr 11;13(4):e0195627. (PMID: 29641545)
Cell Oncol. 2008;30(5):435-50. (PMID: 18791274)
Steroids. 2003 Sep;68(7-8):569-85. (PMID: 12957662)
World Neurosurg. 2017 Jul;103:330-340. (PMID: 28427986)
Pharmacol Ther. 2019 Feb;194:44-58. (PMID: 30189290)
Cancer Cell. 2018 Jan 8;33(1):152. (PMID: 29316430)
Neurology. 2006 Jun 13;66(11):1638-43. (PMID: 16769933)
Neurosci Lett. 2004 Sep 30;368(3):279-84. (PMID: 15364411)
Neuro Oncol. 2017 Jan;19(1):139-141. (PMID: 28031383)
Cancer Cell. 2013 Sep 9;24(3):331-46. (PMID: 23993863)
Sci Rep. 2014 Apr 23;4:4749. (PMID: 24756113)
Semin Cancer Biol. 2021 Feb 25;:. (PMID: 33640445)
Clin Transl Imaging. 2016;4:145-156. (PMID: 27077069)
Science. 2015 Jan 30;347(6221):555-8. (PMID: 25635101)
Psychoneuroendocrinology. 2019 Aug;106:65-76. (PMID: 30954920)
Endocrinology. 2009 Dec;150(12):5438-45. (PMID: 19846611)
Neuro Oncol. 2020 Jul 7;22(7):1030-1043. (PMID: 32047908)
Cell. 2018 Apr 5;173(2):400-416.e11. (PMID: 29625055)
J Genet Psychol. 2021 Mar-May;182(3):149-162. (PMID: 33769215)
Biochemistry. 2005 Jul 26;44(29):9924-35. (PMID: 16026165)
Neurooncol Pract. 2019 Dec;6(6):451-462. (PMID: 31832215)
Tumour Biol. 2015 Feb;36(2):967-72. (PMID: 25315188)
Biochem Pharmacol. 2004 Aug 15;68(4):689-98. (PMID: 15276076)
Am J Med Genet B Neuropsychiatr Genet. 2006 Apr 5;141B(3):222-6. (PMID: 16511838)
Neurobiol Dis. 2020 Nov;145:105060. (PMID: 32877743)
Neuro Oncol. 2020 Feb 20;22(2):240-252. (PMID: 31563962)
Neurobiol Dis. 2015 Feb;74:58-65. (PMID: 25447235)
J Mol Graph. 1993 Dec;11(4):236-44, 235. (PMID: 8136326)
Cancer Cell. 2006 Mar;9(3):157-73. (PMID: 16530701)
J Neurooncol. 2007 Jan;81(1):1-7. (PMID: 16868661)
Int J Mol Sci. 2019 Jun 28;20(13):. (PMID: 31261683)
Endocrinology. 2004 Mar;145(3):1113-23. (PMID: 14630713)
Psychiatr Genet. 2009 Apr;19(2):110-1. (PMID: 19668118)
J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5. (PMID: 22008728)
J Neuroimmune Pharmacol. 2018 Mar;13(1):1-5. (PMID: 28875261)
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1368-1380. (PMID: 31486876)
Neurochem Int. 2002 May;40(6):475-86. (PMID: 11850104)
Cancer Res. 1995 Jun 15;55(12):2691-5. (PMID: 7780986)
Pharmacogenet Genomics. 2012 Jul;22(7):538-50. (PMID: 22547081)
معلومات مُعتمدة: R01 ES007062 United States ES NIEHS NIH HHS; T32 CA059366 United States CA NCI NIH HHS; 800006850 FIU-ORED; R01ES007062-23 United States ES NIEHS NIH HHS
فهرسة مساهمة: Keywords: TSPO; biomarker; glioblastoma; single nucleotide polymorphism; survival
تواريخ الأحداث: Date Created: 20210928 Latest Revision: 20220415
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8471762
DOI: 10.3390/cancers13184525
PMID: 34572751
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13184525